IMPLANET Reports 18% Revenue Growth in Q1 2026

IMPLANET, a medical technology firm, announced a revenue increase of 18% for the first quarter of 2026, amounting to €3.03 million. This growth aligns with seven consecutive quarters of double-digit gains. The company attributes its performance to the expansion of its distribution business, especially the SMTP ultrasonic scalpel, and a significant revenue increase of 167% in the United States.

In France, the company saw an 8% revenue rise, reaching €1.26 million. However, revenue from the Rest of the World decreased by 19%, mainly due to deferred orders from Middle Eastern and Asian countries.

As of March 2026, IMPLANET's cash reserve stood at €1.39 million. The company plans to strengthen its presence in the U.S. and develop its products across strategic locations globally. It aims to become an exclusive distributor for Sanyou Medical’s surgical technologies in Europe and the U.S.